JNJ-86974680

N/A

Report date: 2026/03/14 20:00:17
NME

Base Information

Drug NameJNJ-86974680
Drug Alias NameJNJ-86974680
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2a receptor antagonists
TargetsAdenosine A2a receptor
Therapy Area/IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Enterprise Innovation Inc
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Enterprise Innovation IncJanssen Research & Development Llc
Inactive CompaniesN/A
Active IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A